Product image of Mvasi (Bevacizumab) supplied by GNH India

Mvasi

Active Ingredient:
Bevacizumab
Origin:
EU

Mvasi (Bevacizumab)

Bevacizumab, the active ingredient in Mvasi, is a monoclonal antibody presented as a solution for injection for intravenous use. It targets multiple solid tumours by inhibiting angiogenesis and is indicated for adult patients with several advanced cancers.
GNH India supplies Mvasi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Amgen Technology (Ireland) Uc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mvasi is an anti‑angiogenic monoclonal antibody used in oncology to block tumour blood‑vessel growth.

  • Metastatic colorectal cancer: used with chemotherapy to slow disease progression and improve survival.
  • Non‑small cell lung cancer: combined with standard regimens to enhance response rates.
  • Glioblastoma: administered to limit tumour vascularisation and extend progression‑free survival.
  • Renal cell carcinoma: added to targeted therapy to reduce tumour growth.
  • Ovarian cancer: incorporated in first‑line treatment to increase overall response.
  • Cervical cancer: combined with chemoradiation to improve disease control.

How It Works

  • Bevacizumab binds with high affinity to vascular endothelial growth factor‑A (VEGF‑A), preventing its interaction with VEGF receptors on endothelial cells. This blockade inhibits the VEGF‑driven signalling cascade that promotes new blood‑vessel formation, thereby reducing tumour vascularisation, limiting nutrient supply and hindering cancer cell proliferation.

Side Effects

Common Side Effects

  • Hypertension: elevated blood pressure requiring monitoring and management.
  • Proteinuria: presence of protein in urine, often mild and reversible.
  • Fatigue: generalised tiredness that may affect daily activities.
  • Infusion‑related reactions: flushing, chills, or mild rash during administration.

Serious or Rare Side Effects

  • Arterial thromboembolic events: risk of heart attack or stroke.
  • Gastrointestinal perforation: rare but potentially life‑threatening bowel rupture.
  • Severe hemorrhage: uncontrolled bleeding, especially in patients on anticoagulants.
  • Anaphylaxis: acute allergic reaction requiring immediate medical intervention.

Precautions & Warnings

Mvasi requires careful clinical monitoring due to its potent anti‑angiogenic activity.

  • Pregnancy: safety not established; avoid unless potential benefit outweighs risk.
  • Bleeding risk: assess coagulation status and avoid in patients with active hemorrhage.
  • Wound healing: postpone elective surgery until drug clearance is confirmed.
  • Hypertension: monitor blood pressure regularly and treat elevations promptly.
  • Infusion: administer under medical supervision with emergency equipment available.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Bevacizumab may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

  • Concurrent anticoagulants: increased risk of severe bleeding.
  • Combination with other anti‑angiogenic agents: additive toxicity and vascular complications.
  • Live vaccines: heightened risk of infection due to impaired angiogenesis.

Moderate Interactions (Monitor Closely)

  • Chemotherapy agents causing myelosuppression: monitor blood counts closely.
  • NSAIDs: may exacerbate bleeding tendencies.

Frequently Asked Questions

Mvasi is a brand of bevacizumab, an anti‑angiogenic monoclonal antibody indicated for the treatment of several advanced solid tumours, including metastatic colorectal cancer, non‑small cell lung cancer, glioblastoma, renal cell carcinoma, ovarian cancer and cervical cancer in adult patients.

Bevacizumab binds to VEGF‑A, a key growth factor that stimulates new blood‑vessel formation. By blocking VEGF‑A from activating its receptors on endothelial cells, the drug reduces tumour angiogenesis, limiting the blood supply that cancer cells need to grow and spread.

The dose of Mvasi is determined by the prescribing oncologist based on the specific cancer type, patient weight, treatment regimen and clinical response. Dosage adjustments are made according to established guidelines and individual patient factors.

Safety of bevacizumab in pregnancy and lactation has not been established. It is generally avoided in pregnant or nursing women unless the potential therapeutic benefit justifies the potential risk to the fetus or infant.

To order Mvasi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Mvasi (bevacizumab) is a fully humanised monoclonal antibody targeting VEGF‑A, whereas many alternatives are small‑molecule tyrosine‑kinase inhibitors that block multiple receptors. Bevacizumab offers a specific mechanism with a well‑characterised safety profile, but selection depends on tumour type, prior therapy and physician preference.

Mvasi should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until ready for preparation and administration.

Mvasi is supplied as a sterile solution for injection and is given intravenously by a qualified healthcare professional. The infusion is typically administered over a period of 30‑90 minutes, depending on the prescribed dose and patient tolerance.

Serious risks include arterial thromboembolic events such as heart attack or stroke, gastrointestinal perforation, severe hemorrhage, and anaphylactic reactions. Patients should be monitored closely for signs of these events, and treatment should be discontinued if they occur.

Mvasi is contraindicated in patients with known hypersensitivity to bevacizumab or any of its excipients, those with active bleeding disorders, recent major surgery, or uncontrolled hypertension. Caution is also advised for patients with recent arterial thrombotic events.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Bevacizumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT